The MD Anderson group initially described results with Hyper-CVAD/MA, [28] a more intensive regimen that includes hyperfractionated cyclophosphamide and alternating high-dose methotrexate–cytarabine ...

Results of a phase I study of bendamustine in combination with ofatumumab, carboplatin, and etoposide (BOCE) for refractory or relapsed aggressive B-cell non-Hodgkin lymphomas (NHL). This is an ASCO ...

Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) from ...

Pediatric-inspired protocols and hyper-CVAD conferred comparable survival for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to study ...

Forty patients with T-ALL/LL were enrolled with a median age of 38 years (19–78 years). Twenty-three patients (58%) had T-ALL and 17 (43%) had LL. The performance status was ⩽2 in 36/40 (90%) patients ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

Modern chemoimmunotherapies have produced higher response rates and improved survival in mantle cell lymphoma (MCL); however, disease relapse remains a challenge. The availability of various ...